Modeling amyloid therapy potential on a population level: An adaptation of the MISCAN‐Dementia model

We are adapting the MISCAN-Dementia model to estimate the population-wide impact of amyloid-targeting therapies. In this presentation, we will present the model changes and methodological considerations we have encountered, as well as first estimates of the eligible population. To capture the impact of amyloid-targeting therapies fully, the next steps include estimating the population-wide harms and benefits of amyloid-targeting therapies.